AR054000A1 - Compuesto de n-(fenilpropil)-sulfonamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, producto de combinacion que comprende dicho compuesto y metodo para prepararlo - Google Patents
Compuesto de n-(fenilpropil)-sulfonamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, producto de combinacion que comprende dicho compuesto y metodo para prepararloInfo
- Publication number
- AR054000A1 AR054000A1 ARP060100542A ARP060100542A AR054000A1 AR 054000 A1 AR054000 A1 AR 054000A1 AR P060100542 A ARP060100542 A AR P060100542A AR P060100542 A ARP060100542 A AR P060100542A AR 054000 A1 AR054000 A1 AR 054000A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- alkyl
- halogen
- formula
- alkoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 11
- 238000000034 method Methods 0.000 title abstract 4
- 239000013066 combination product Substances 0.000 title abstract 2
- 229940127555 combination product Drugs 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 150000002367 halogens Chemical class 0.000 abstract 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 4
- 125000001188 haloalkyl group Chemical group 0.000 abstract 4
- 229910052794 bromium Inorganic materials 0.000 abstract 3
- 229910052740 iodine Inorganic materials 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000012453 solvate Substances 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 230000008878 coupling Effects 0.000 abstract 2
- 238000010168 coupling process Methods 0.000 abstract 2
- 238000005859 coupling reaction Methods 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 239000000047 product Substances 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 102000018899 Glutamate Receptors Human genes 0.000 abstract 1
- 108010027915 Glutamate Receptors Proteins 0.000 abstract 1
- CGYMAERTNXAAHW-UHFFFAOYSA-N O=S(=O)NCCCC1=CC=CC=C1 Chemical compound O=S(=O)NCCCC1=CC=CC=C1 CGYMAERTNXAAHW-UHFFFAOYSA-N 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 230000000561 anti-psychotic effect Effects 0.000 abstract 1
- -1 boronate compound Chemical class 0.000 abstract 1
- 150000001642 boronic acid derivatives Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000006735 epoxidation reaction Methods 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 230000009466 transformation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un compuesto de N-(fenilpropil)-sulfonamida que tiene la formula (1), o una de sus sales o solvatos en la que, R1 se selecciona de alquilo C1-6, halogeno-alquilo C1-6, alquenilo C2-6, amino, mono-alquil(C1-4)amino y di-alquil(C1-4)amino; R2, R3 y R6, que puede ser iguales o diferentes, se selecciona cada uno independientemente de H, halogeno, alquilo C1-6, halogenoalquilo C1-6 y alcoxi C1-4; cada R4, que pueden ser iguales o diferentes, se selecciona de alquilo C1-6, halogeno, halogenoalquilo C1-6, alcoxi C1-4, halogeno-alcoxi C1-4 y ciano; p se selecciona de 0, 1 y 2; y R5 es fenilo o un heterociclilo aromático, cualquiera de los cuales está opcionalmente sustituido con uno o más grupos Y; cada grupo Y se selecciona independientemente del grupo que consiste en: alquilo C1-6, halogeno, halogenoalquilo C1-6, alcoxi C1-4, halogenoalcoxi C1-4, ciano, -(CH2)qNR5aSO2R5b, -(CH2)qNR5a(C=O)R5d, -(CH2)qNR5a(C=O)N(R5c)2, -(CH2)q(C=O)R5d, -(CH2)qSO2R5b; donde R5a y cada R5c, que pueden ser iguales o diferentes, se selecciona de H y alquilo C1-6; R5b se selecciona de alquilo C1-6 y halogenoalquilo C1-6; R5d se selecciona de alquiloc1-*6, alcoxi C1-4 y halogenoalquilo C1-6; o R5a y R5b, R5a y R5c, o R5a y R5d, cuando sea adecuado, junto con los átomos conectores pueden formar un anillo de 5 o 6 miembros; y q es 0, 1 o 2; en el caso en el que hay dos o más grupos Y presentes, dos de ellos juntos pueden formar un grupo cíclico seleccionado de -(CH2)rOR5eO(CH2)s- y -(CH2)tOR5e- donde R5e es un grupo seleccionado de alquileno C1-4 o halogenoalquileno C1-4; r y s son cada uno independientemente 0, 1 o 2, y t es 2 o 3. Composicion farmacéutica que comprende un compuesto de formula (1), y al menos un vehículo o diluyente farmacéuticamente aceptables. Uso del compuesto para la fabricacion de un medicamento para tratar o prevenir una enfermedad o una afeccion causadas por una reduccion o desequilibrio en la funcion del receptor de glutamato. Producto de combinacion que comprende un compuesto de formula (1), o una de sus sales o solvatos, con un antipsicotico. Método para prepara dicho compuesto. Reivindicacion 22: Un método para preparar un compuesto de acuerdo con una cualquiera de las reivindicaciones 1 a 13, caracterizado porque comprende: a) acoplar un compuesto de formula (2) donde X es un grupo lábil tal como halogeno (por ejemplo Cl, Br o I) con un derivado de ácido boronico de formula (3); o b) acoplar un compuesto de boronato de formula (4) con un compuesto R5-X donde X es un grupo lábil tal como halogeno (por ejemplo Br o I) y después opcionalmente preparar una sal o solvato del producto. Reivindicacion 24: Un método para preparar un compuesto segun una cualquiera de las reivindicaciones 1 a 13 en forma quiral, caracterizado porque comprende la etapa de epoxidar estereoselectivamente un estireno (X) adecuado, donde X es un grupo lábil tal como halogeno (por ejemplo Cl, Br o I),seguido de la transformacion del producto de la epoxidacion en un compuesto de la presente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0503155A GB0503155D0 (en) | 2005-02-15 | 2005-02-15 | Novel compounds |
| GB0601612A GB0601612D0 (en) | 2006-01-26 | 2006-01-26 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054000A1 true AR054000A1 (es) | 2007-05-30 |
Family
ID=36253489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060100542A AR054000A1 (es) | 2005-02-15 | 2006-02-15 | Compuesto de n-(fenilpropil)-sulfonamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, producto de combinacion que comprende dicho compuesto y metodo para prepararlo |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7790758B2 (es) |
| EP (1) | EP1848695B1 (es) |
| JP (1) | JP2008530162A (es) |
| AR (1) | AR054000A1 (es) |
| AT (1) | ATE517867T1 (es) |
| PE (1) | PE20061127A1 (es) |
| TW (1) | TW200640863A (es) |
| WO (1) | WO2006087169A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SA08290520B1 (ar) | 2007-08-22 | 2012-02-22 | استرازينيكا ايه بي | مشتقات سيكلو بروبيل أميد وتركيبات صيدلية تحتوي عليها لعلاج حالة مرضية سببها مستقبلات هيستامين h3 |
| TW201039825A (en) | 2009-02-20 | 2010-11-16 | Astrazeneca Ab | Cyclopropyl amide derivatives 983 |
| SG10201501226VA (en) * | 2010-02-18 | 2015-04-29 | Astrazeneca Ab | New crystalline form of a cyclopropyl benzamide derivative |
| EP3718547A1 (en) | 2011-10-03 | 2020-10-07 | The University of Utah Research Foundation | Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
| CN104379559B (zh) * | 2012-04-27 | 2016-11-09 | 葛兰素集团有限公司 | 化合物 |
| US8633182B2 (en) | 2012-05-30 | 2014-01-21 | Boehringer Ingelheim International Gmbh | Indanyloxyphenylcyclopropanecarboxylic acids |
| EP3311842A1 (en) | 2013-06-13 | 2018-04-25 | VeroScience LLC | Compositions and methods for treating metabolic disorders |
| CN110088089B (zh) | 2016-10-25 | 2023-08-29 | 勃林格殷格翰国际有限公司 | 苄基氨基吡啶基环丙烷甲酸、药物组合物及其用途 |
| EP3544958B1 (en) | 2016-11-28 | 2021-03-24 | Boehringer Ingelheim International GmbH | Indanylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| JP7023969B2 (ja) | 2017-01-26 | 2022-02-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 |
| CN110248929B (zh) | 2017-01-26 | 2023-05-12 | 勃林格殷格翰国际有限公司 | 苄基氨基吡嗪基环丙烷甲酸、其药物组合物和用途 |
| EP3573969A1 (en) | 2017-01-26 | 2019-12-04 | Boehringer Ingelheim International GmbH | Benzyloxypyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| US10253004B2 (en) | 2017-01-26 | 2019-04-09 | Boehringer Ingelheim International Gmbh | Indanylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| JP7050791B2 (ja) | 2017-01-26 | 2022-04-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルオキシピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1276153B1 (it) * | 1995-11-17 | 1997-10-27 | Roberto Pellicciari | Derivati di glicina ad attivita' antagonista dei recettori metabotropi del glutammato |
| GB9702194D0 (en) * | 1997-02-04 | 1997-03-26 | Lilly Co Eli | Sulphonide derivatives |
| EP1694638A1 (en) * | 2003-12-15 | 2006-08-30 | Japan Tobacco, Inc. | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof |
| EP1694410B1 (en) * | 2003-12-15 | 2010-04-14 | Japan Tobacco, Inc. | Cyclopropane derivatives and pharmaceutical use thereof |
| EP1786769A1 (en) * | 2004-08-09 | 2007-05-23 | Glaxo Group Limited | Compounds which potentiate glutamate receptor and uses thereof in medicine |
-
2006
- 2006-02-13 PE PE2006000161A patent/PE20061127A1/es not_active Application Discontinuation
- 2006-02-13 WO PCT/EP2006/001342 patent/WO2006087169A1/en not_active Ceased
- 2006-02-13 EP EP06706948A patent/EP1848695B1/en active Active
- 2006-02-13 JP JP2007555519A patent/JP2008530162A/ja active Pending
- 2006-02-13 AT AT06706948T patent/ATE517867T1/de not_active IP Right Cessation
- 2006-02-13 TW TW095104677A patent/TW200640863A/zh unknown
- 2006-02-13 US US11/816,284 patent/US7790758B2/en not_active Expired - Fee Related
- 2006-02-15 AR ARP060100542A patent/AR054000A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PE20061127A1 (es) | 2006-10-21 |
| WO2006087169A1 (en) | 2006-08-24 |
| EP1848695B1 (en) | 2011-07-27 |
| US20080167351A1 (en) | 2008-07-10 |
| ATE517867T1 (de) | 2011-08-15 |
| JP2008530162A (ja) | 2008-08-07 |
| US7790758B2 (en) | 2010-09-07 |
| TW200640863A (en) | 2006-12-01 |
| EP1848695A1 (en) | 2007-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| AR054000A1 (es) | Compuesto de n-(fenilpropil)-sulfonamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, producto de combinacion que comprende dicho compuesto y metodo para prepararlo | |
| AR066583A1 (es) | Derivados de 3,3-espiroindolinona | |
| AR077328A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| AR066562A1 (es) | Derivados de pirrol condensados; una formulacion farmaceutica en base al compuesto y su uso para preparar medicamentos | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| CR9459A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| UY29705A1 (es) | " inhibidores macrocíclicos del virus de la hepatitis c" | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| AR063331A1 (es) | Derivados de biaril eter urea y composiciones farmaceuticas | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
| ECSP055774A (es) | Nuevo medicamento para el tratamiento de la enfermedad pulmonar obstructiva crónica | |
| NO20080391L (no) | Pyrazolbaserte LXR modulatorer | |
| AR081994A1 (es) | Derivados de [1,8]naftiridina, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para el tratamiento de enfermedades inducidas por quinasas, en particular diferentes tipos de canceres | |
| AR052902A1 (es) | Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa | |
| EA200870362A1 (ru) | Способ получения производных лактамида, новые производные лактамида и препараты, содержащие производные лактамида | |
| AR044045A1 (es) | Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion | |
| AR049646A1 (es) | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados | |
| AR054214A1 (es) | Compuestos derivados de 1, 1 - dioxotiadiazina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la infeccion por el virus de la hepatitis c. | |
| AR068115A1 (es) | Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |